Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Completed 4Unknown 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Classical hematology 1

Conditions

Multiple Myeloma 1Jacobs syndrome 1Cancer Treatment Induced Thrombocytopenia 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 284Drug Therapy 244apatinib 242Bevacizumab 230camrelizumab 214Etoposide 200Irinotecan 177Doxorubicin 175Leucovorin 162Dexamethasone 160sintilimab 142pembrolizumab 140anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × Thrombopoietin × Clear all
NCT05411705 2024-03-01

Circular

The First Affiliated Hospital of Dalian Medical University

Phase 4 Unknown
165 enrolled
Classical hematology

Cancer Treatment Induced Thrombocytopenia

NCT02572596 2017-02-09

Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients

Beijing Chao Yang Hospital

Phase NA Unknown
200 enrolled
Plasma cell

Jacobs syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡